Actorise 25MCG Injection (0.42ml)
Actorise 25MCG Injection is a formulation of the synthetic form of a hormone known as erythropoietin (EPO), which is principally involved in the production of red blood cells (RBCs). The active pharmaceutical ingredient in Actorise is Darbepoetin alfa, which is an analog of human erythropoietin, created through recombinant DNA technology. Actorise is intricately designed to stimulate the bone marrow to enhance the production of RBCs, thereby increasing the oxygen-carrying capacity of the blood. Clinically, it is employed in situations where there is a deficiency or suppression of endogenous EPO, commonly in chronic kidney disease (CKD) or as a consequence of certain therapies like chemotherapy that induce anemia. Administered intravenously or subcutaneously, Actorise is a vital therapeutic agent that addresses anemia without requiring blood transfusions, which can be associated with risks such as infection transmission or immune reactions.
Essential Drug Facts
| Dosage form | SC(Subcutaneous) Injection |
|---|---|
| Chemical Class | Amino acids, Peptides analogues |
| Habit Forming | No |
| Systemic Category | Cardiovascular & Hematopoietic system |
| Action Class | Erythropoiesis-stimulating agent (ESA) |
What are the Indication / Medical Uses of Actorise 25MCG Injection (0.42ml)
Actorise 25MCG Injection is indicated in the treatment of anemia associated with chronic kidney disease, both in adults and pediatric patients. It is also used to manage anemia induced by cancer chemotherapy in patients with non-myeloid malignancies and as a preoperative measure to reduce allogeneic blood transfusions in patients undergoing elective, non-cardiac, non-vascular surgery.
How Does Actorise 25MCG Injection (0.42ml) Benefit You?
Actorise 25MCG Injection is advantageous in elevating hemoglobin levels, thereby reducing the symptoms of anemia such as fatigue, weakness, and shortness of breath. Patients with enhanced hemoglobin levels due to Actorise treatment may experience improved quality of life and decreased necessity for blood transfusions with their associated risks.
.svg)
Actorise 25MCG Injection (0.42ml) Action Mechanism
Actorise 25MCG Injection exerts its therapeutic effect by binding to the erythropoietin receptor on progenitor stem cells in bone marrow, initiating a series of intracellular signaling cascades. It promotes the survival, proliferation, and differentiation of the erythroid precursors into mature RBCs.
How should Actorise 25MCG Injection (0.42ml) be used
Actorise is to be administered either as a subcutaneous injection or intravenous infusion. The dosage and frequency of administration depend on the specific clinical scenario, the patient's weight, and their hemoglobin levels. It is important that the injection is given under the supervision of a qualified physician (doctor or healthcare professional) following the recommended guidelines.
When is the best time to take Actorise 25MCG Injection (0.42ml) ?
The timing for administering Actorise 25MCG Injection is typically determined by the doctor (healthcare provider) based on the patient’s individual treatment schedule and needs.
How does it affect me if I overdose?
An overdose of Actorise 25MCG Injection may potentially lead to excessive erythropoiesis, which can increase the risk of thrombotic events, hypertension, and in severe cases, congestive heart failure or myocardial infarction.
.svg)
How does it affect me if I miss a dose?
Missing a dose of Actorise 25MCG Injection could result in a decline in hemoglobin levels, which may revert the patient back to a state of anemia, with a resurgence of related symptoms.
Drug Adverse Reactions of Actorise 25MCG Injection (0.42ml)
The administration of Actorise can induce adverse reactions such as hypertension, flu-like symptoms, edema, and pain at the injection site. Severe but rare side effects include thrombosis, seizure, and antibody development that can lead to pure red cell aplasia (PRCA).
Actorise 25MCG Injection (0.42ml) Tablet is contraindicated in following conditions
Actorise 25MCG Injection is contraindicated in individuals with uncontrolled hypertension, in those with a known hypersensitivity to darbepoetin alfa or any of the formulation's components, and in patients with pure red cell aplasia following treatment with erythropoietin therapy.
Actorise 25MCG Injection (0.42ml) Safety Warnings and Precautions
There are no known direct interactions between moderate alcohol consumption and Actorise; nonetheless, individual counseling is advised.
Patients with known hypersensitivity to darbepoetin alfa should avoid using Actorise.
The use of Actorise during pregnancy should be limited to situations where the benefits outweigh the potential risks to the developing fetus. This decision should be made only after careful consideration and consultation with a healthcare provider.
While used in pediatric patients for CKD.induced anemia, safety and efficacy can vary based on age and developmental stage.
There is a lack of significant studies to conclusively determine the excretion of darbepoetin alfa in human milk. Caution should be exercised when administering to nursing mothers.
Actorise does not typically influence the ability to drive or use machines; however, individual discretion is advised if patients experience adverse effects that might impair these abilities.
Actorise is indicated for use in patients with CKD; however, such patients should be closely monitored due to altered pharmacokinetics.
No specific concerns regarding pulmonary function have been noted, but individual risks should be evaluated by a healthcare provider.
Patients with liver dysfunction may have altered pharmacodynamics; close monitoring is warranted.
Patients with cardiovascular diseases should be monitored as Actorise may increase the risk of thrombotic events.
Interactions between Actorise 25MCG Injection (0.42ml)
Actorise could interact with other drugs that may have a negative impact. Specifically, cyclosporine levels have been observed to be affected when started on erythropoietin treatment, along with any agents that may increase the risk of thrombosis when used concomitantly.
How to store and dispose of Actorise 25MCG Injection (0.42ml)
It is recommended to store Actorise under refrigeration at a temperature range of 2 to 8 °C and to avoid freezing. It is essential to protect the product from light and store it in the original packaging until use to maintain its potency. Disposal of any unused product or waste should be carried out in accordance with local regulations.
Here are a few quick tips for Actorise 25MCG Injection (0.42ml)
Before commencing treatment with Actorise, patients are encouraged to discuss their complete medical history with their healthcare provider. It is vital to adhere to scheduled doses and monitor hemoglobin levels regularly to ensure the medication operates at the optimal level. Patients are recommended to look out for any signs of adverse reactions, particularly those related to thrombotic events or hypertension, as immediate medical intervention may be necessary in such situations.
Parameters that should be monitored Actorise 25MCG Injection (0.42ml)
Regular monitoring of hemoglobin levels, blood pressure, complete blood counts (CBCs), and iron is necessary to gauge efficacy and modify dosage as required. Evaluating renal function in patients with CKD and monitoring for signs of cardiovascular events is also recommended.
Considerations related to diet Actorise 25MCG Injection (0.42ml)
While under treatment with Actorise, maintaining a healthy and balanced diet that supports red blood cell production is advisable. This often includes foods rich in iron, folic acid, and vitamin B12.
Question and Answer (FAQ)
Q: What conditions are treated with Actorise 25MCG Injection?
A: Actorise is used to treat anemia in chronic kidney disease patients, in those undergoing chemotherapy for non-myeloid cancers, and in the preoperative setting to reduce the need for transfusions.
Q: How often should Actorise 25MCG Injection be given?
A: The dosing regimen for Actorise is determined by a healthcare professional based on individual patient needs.
Q: Can Actorise 25MCG Injection cause high blood pressure?
A: Yes, one of the side effects of Actorise is hypertension, and blood pressure should be monitored during therapy.
Q: Is Actorise recommended for pregnant women?
A: Actorise should only be used during pregnancy if necessary and after a thorough assessment of risks versus benefits.
Q: Can breastfeeding mothers use Actorise 25MCG Injection?
A: Nursing mothers should use Actorise with caution and only if advised by a healthcare provider.
Q: How is Actorise 25MCG Injection given?
A: It is administered through a subcutaneous injection or intravenous infusion by a healthcare professional.
Q: How should Actorise be stored?
A: Actorise should be refrigerated and protected from light.
Q: Can children receive Actorise 25MCG Injection?
A: Actorise is used in children with CKD-induced anemia, but specific dosage and administration should be managed by a healthcare provider.
Q: Are there any drugs that interact with Actorise?
A: Yes, other medications may interact with Actorise, including those that affect blood viscosity or cyclosporine.
Q: Can Actorise 25MCG Injection cause allergic reactions?
A: Allergic reactions can occur, especially in individuals who are hypersensitive to darbepoetin alfa or other ingredients in the formulation.
Reviews
There are no reviews yet.